Orexo strengthens its clinical and regulatory team with the appointment of three senior executives

Orexo strengthens its clinical and regulatory team with the appointment of three
senior executives

FOR MEDIA INFORMATION
Simon Vane Percy / Sarah Roberts
Vane Percy & Roberts
(T) 01737 821891 / 892
(F) 01737 821899
(e) simon@vanepercy.com / sarah@vanepercy.com 

Orexo (OMX Midcap:ORX.) has strengthened its clinical and regulatory team with
the appointment of three senior executives - Mats Eriksson PhD, VP Research and
Clinical Development and Medical Director for Orexo, Christina Ståhl MSc. Pharm,
Vice President Regulatory Affairs, and Anne Marie Ciupitu MSc, PhD, Director
QA/QC.

Zsolt Lavotha, President and CEO of Orexo AB said, “We are delighted to have
been able to attract such experienced people to Orexo.  As we are increasing the
number of new products in development it is imperative that we ensure that we
have the ability to plan the best clinical development and regulatory strategy
to be able to bring products to market as quickly as possible.” 

Mats Eriksson PhD, who is an associate professor of Anaesthesia and Intensive
Care at Uppsala University Hospital, has previously worked for Sanofi
Synthelabo, Novo Nordisk and, was prior to joining Orexo, Medical Manager of
Wyeth Sweden.

Christina Ståhl MSc. Pharm, who is a registered pharmacist, has been working in
clinical development and regulatory affairs for the last twenty years with Kabi
Vitrum, Pharmacia, Astra Zeneca and was, prior to joining Orexo, Regulatory
Affairs Manager/QP for Roche Sweden.

Anne Marie Ciupitu MSc, PhD, has been working as a QA specialist for the last
six years with Wyeth Biotech in Sweden.  Before joining Orexo she had been
appointed Quality Assurance Manager for the company.

For further information contact: 

Zsolt Lavotha, President & CEO
Tel:	+46 (0)18 780 88 12
Email:	zsolt.lavotha@orexo.se

Claes Wenthzel, Executive Vice President & CFO
Tel:	+46 (0)18 780 88 44
Email:	claes.wenthzel@orexo.se


NOTES TO EDITORS:

About Orexo 

Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo's drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs. 

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets.

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase and two under formulation
development.

Orexo is listed on the OMX Nordic List Mid Cap (ticker;ORX).